mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com)
Looking for a particular mAbxience employee's phone or email?
The mAbxience annual revenue was $59.7 million in 2026.
Jurgen van Broeck is the CEO of mAbxience.
920 people are employed at mAbxience.
The NAICS codes for mAbxience are [32, 3254, 32541, 325].
The SIC codes for mAbxience are [28, 283].